Federal Circuit Offers Path Through Section 101 Thicket for Biotech Method Patents

by Foley Hoag LLP

Foley Hoag LLP

In its July 5, 2016 decision in Rapid Litigation Management Ltd and In Vitro, Inc. v. CellzDirect, Inc. and Invitrogen Corp., the Federal Circuit held that patent claims directed to an improved method of cryopreserving certain liver cells constitutes patent-eligible subject matter under 35 U.S.C. § 101. The district court had granted summary judgment of invalidity, holding that the claims were directed to a law of nature: namely, that hepatocytes can survive multiple freeze-thaw cycles. Chief Judge Proust, joined by Judges Moore and Stoll, reversed the district court and, in doing so, shed some light on the Supreme Court’s two-step subject-matter eligibility test as applied to inventions in the life sciences field.

The test articulated by the Supreme Court in the Alice and Mayo cases requires a court to determine (1) whether the claims at issue are directed to one of the judicial exceptions, such as a law of nature and (2) whether the additional claim limitations beyond the ineligible subject matter are sufficient to transform the process into an inventive application of otherwise ineligible subject matter. The lower courts have struggled in their application of this test, including what it means for a claim to be “directed to” a law of nature or natural phenomenon.

The CellzDirect decision offers meaningful guidance as to the proper application of the Alice/Mayo test. As to the first step, the Federal Circuit held that the district court erred in concluding that the claims are “directed to” a law of nature, finding instead that the claims “are directed to a new and useful laboratory technique for preserving hepatocytes.” The Court emphasized that the inventors “employed their natural discovery [that these cells can survive multiple freeze-thaw cycles] to create a new and improved way of preserving hepatocytes for later use.”

Importantly, the decision underscored the distinction between claims “directed to” and claims “involving” a law of nature. The Court commented that failing to draw this distinction would lead, incorrectly, to findings that a variety of patentable methods were “directed to” patent ineligible subject matter—e.g., methods of “producing a new compound (as directed to the individual components’ ability to combine to form a new compound), treating cancer with chemotherapy (as directed to cancer cells’ inability to survive chemotherapy), or treating headaches with aspirin (as directed to the human body’s natural response to aspirin)”. The Court’s endorsement of claims such as these will come as good news to life sciences innovators. Where, as here, the claimed invention can be characterized as merely “involving” a natural law or phenomenon, it will satisfy section 101, and further inquiry under the Alice/Mayo test will be unnecessary.

In dicta, the Court also performed the second step of the test, providing further guidance on its application. The district court had reasoned that because each individual recited step of the claim was known independently in the art, the claim recited nothing more than “well understood, routine, conventional activity already engaged in by the scientific community.” The Federal Circuit found this analysis to be erroneous, because it improperly considered each step alone rather than looking at the claim as a whole. The Court explained that, “[t]he individual steps of freezing and thawing were well known, but a process of preserving hepatocytes by repeating those steps was itself far from routine.” On this basis, the Court concluded that even if the claims had been “directed to” patent ineligible subject matter in step one of the Alice/Mayo test, the claims still would be patentable because the steps, as a whole, “’transform[] the process into an inventive application’ of the patent-ineligible concept.” The decision stresses that “patent-eligibility does not turn on ease of execution or obviousness of the application [of the natural law or phenomenon].” Instead, those questions are examined under other provisions of the Patent Act, including 35 U.S.C. § 103.

This decision is welcome guidance for many in the life sciences industry who were disappointed by the Supreme Court’s recent denial of certiorari in the high-profile Ariosa v. Sequenom case, where the Federal Circuit found Ariosa’s diagnostic claims ineligible. One lesson from CellzDirect decision is that patent attorneys should strive to craft claims that “pass” step one of the Alice/Mayo test. To do so, they should draft method claims to recite the specific, concrete steps performed in the method and should avoid reciting judicial exceptions where possible. For example, if a diagnostic claim can be presented as a series of concrete steps performed by a scientist for detecting an analyte, the claim should not include an unnecessary “wherein” clause reciting a correlation between the analyte and a disease state. Indeed, in Example 29 of its May 2016 Life Sciences Subject Matter Eligibility Examples, the USPTO appears to have anticipated the more rigorous step one analysis adopted by the Federal Circuit in this case.

And if a claim nevertheless is determined to be “directed to” ineligible subject matter such that patentability will depend on Alice/Mayo’s step two, the CellzDirect decision is an important tool to buttress an argument that the specific, ordered combination of steps recited in the claim as a whole are new, unconventional, and, therefore, patent-eligible, even if the individual steps in isolation might be known. Similarly, the CellzDirect decision can be used to push back on an examiner who blurs step two of the Alice/Mayo test with an obviousness analysis.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Foley Hoag LLP | Attorney Advertising

Written by:

Foley Hoag LLP

Foley Hoag LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.